Dicerna Pharmaceuticals, Inc. announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna’s investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD). The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of DCR-AUD in healthy volunteers. The trial will also assess the interaction between DCR-AUD administration and alcohol consumption using standardized Ethanol Interaction Assessments (EIA) performed serially over the trial’s duration. AUD is characterized by the inability to stop or control alcohol use despite social, occupational or health consequences. Treatment approaches include psychosocial support and pharmacotherapy, but many individuals with AUD do not receive treatment, and currently available pharmacotherapies are not widely prescribed. Overall, of the estimated 14 million individuals in the U.S. with AUD, fewer than 1.4 million receive treatment of any kind. The randomized, double-blind Phase 1 clinical trial (NCT05021640) will evaluate single doses of DCR-AUD compared to placebo in up to 36 healthy volunteers over a 24-week observation period.